Given the well-established role of MYC protein in driving lymphoma progression and the numerous preclinical studies in which suppression of MYC activity triggered regression of many tumor types considered MYC-driven[41-44] - including those where MYC is not deemed the initiating oncogenic lesion[45,46], it is clear that MYC inhibition could represent an effective treatment avenue. The gene discussed is MYC; the disease is neoplasm.